Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (ERASER)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04305249 |
|
Recruitment Status :
Recruiting
First Posted : March 12, 2020
Last Update Posted : January 12, 2023
|
Sponsor:
Antengene Therapeutics Limited
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Antengene Corporation ( Antengene Therapeutics Limited )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | May 20, 2023 |
| Estimated Study Completion Date : | August 20, 2023 |